A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Status:
Completed
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
This research study is studying the use of a targeted therapy called LY SARM, which is an
investigational drug from a new class of molecules called Selective Androgen Receptor
Modulators (SARMs) as a possible improvement in quality of life for participants who have
undergone radical prostatectomy. Androgens are a group of hormones that play a role in male
traits and reproductive activity.
The names of the study interventions involved in this study are:
- LY2452473